Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

NCT06714838

Status	RECRUITING
Phase	Phase 3
Sponsor	Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (12)

- CIDP according to the EAN/PNS criteria (1)
- Untreated
- Men and women aged between 18 and 80 years
- Sufficient CIDP-related disability, as judged by treating physician to warrant IVIg and RTX treatment
- Capable of giving signed informed consent

... and 7 more (see full listing online)

Exclusion (15)

- Paranodopathy with demonstrated (paranodal) antibodies, previously considered part of CIDP spectrum (in these cases rituximab is preferred treatment)
- Use of drugs associated with a demyelinating neuropathy in the last six months.
- Known serious adverse events with previous IVIg or RTX treatment. Hypersensitivity to RTX or any component of the formulation. Hypersensitivity to the human immunoglobulins or to any of the excipients. Known selective IgA deficiency patients who developed antibodies to IgA.
- Positive hepatitis B and C serology suggesting active/untreated infection (HBsAg, anti-HB core en anti-HBs and HCV antibody (IgG))
- Ongoing immunosuppressive treatment for other indications.

... and 10 more (see full listing online)

Locations (1 total)

Amsterdam UMC, Amsterdam, Netherlands